1. 4-(2-(benzenesulfonamido)ethyl)phenoxyacetic Acid
2. Bm 13,177
3. Bm 13.177
4. Bm 13177
5. Bm-13177
6. Sk And F 95587
7. Sk And F-95587
8. Skf 95587
9. Skf-95587
1. Bm-13177
2. 72131-33-0
3. Sk&f 95587
4. Bm 13.177
5. Bm 13177
6. Sk&f-95587
7. Acetic Acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)-
8. (p-(2-benzenesulfonamidoethyl)phenoxy)acetic Acid
9. Chembl8273
10. 74574co5a6
11. Bm-13.177
12. Sulotrobanum [latin]
13. Sulotrobanum
14. Skf 95587
15. Sulotroban [usan:inn:ban]
16. Unii-74574co5a6
17. 2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic Acid
18. (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)acetic Acid
19. Sulotroban [inn]
20. Sulotroban (usan/inn)
21. Sulotroban [usan]
22. Sulotroban [mart.]
23. Schembl34187
24. Dtxsid80222440
25. Bdbm50002765
26. Pdsp1_000740
27. Pdsp2_000728
28. D05970
29. 4-(2-benzenesulfonylaminoethyl)phenoxyacetic Acid
30. 4-[2-(benzene-sulphonamido)-ethyl]-phenoxyacetic Acid
31. Q27266250
32. [4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic Acid
33. [4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic Acid (bm 13177)
34. [4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic Acid(sulotroban)
Molecular Weight | 335.4 g/mol |
---|---|
Molecular Formula | C16H17NO5S |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 8 |
Exact Mass | 335.08274382 g/mol |
Monoisotopic Mass | 335.08274382 g/mol |
Topological Polar Surface Area | 101 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 459 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
LOOKING FOR A SUPPLIER?